GENOMMA LAB INTERNACIONAL ANNOUNCES LEADERSHIP SUCCESSION PLAN

Jorge Brake Maintains Active Role

Continues as Active Vice Chairman of the Board of Directors

MEXICO CITY, Nov. 28, 2022 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, announces a leadership succession plan that positions the Company to continue driving profitable growth and delivering on the Company's vision, as CEO Jorge Brake has informed the Board of his intention to transition from the CEO role while maintaining active involvement in the Company's future. Mr. Brake will be appointed Active Vice Chairman of the Board of Directors, pending approval at Genomma's next Annual General Shareholders Meeting to be held in April 2023.

In accordance with the Company's leadership succession plan, Mr. Rodrigo Herrera, Chairman of the Board informs that Marco Sparvieri, currently Genomma Lab's Chief Operating Officer, will succeed Jorge Brake as Chief Executive Officer.  Genomma's succession plan ensures a six month transition period during which Mr. Brake and Mr. Sparvieri will be collaborating closely.

Mr. Brake, in his ongoing role as Active Vice Chairman, will remain actively involved in the Company's strategic direction, corporate external relations, investor relations, new business opportunities and expansion, as well as the next phase of Genomma's organizational transformation with important related oversight and involvement in shaping the Company's future direction. Further, he will remain involved in mentoring and counselling Genomma's operating executives as they develop within the Company. He will also actively participate in relevant company decisions as member of several Executive Committees that have been approved by the Board of Directors as part of Genomma's renewed Governance Model.

"It has been an extraordinary experience to lead Genomma's turnaround over these past four years and work with our outstanding people to transform Genomma's organization, strengthen our culture through a growth-mindset evolution, and position the Company for even higher levels of growth and success. With a strong foundation and clear trajectory in place, now is the right time to implement our succession plan," said Brake. "During Marco Sparvieri's eight years with Genomma he has demonstrated leadership excellence and a strong track record of delivering results through an outstanding execution of the company strategy. His passion for innovation and teamwork are evident in our many achievements. The Board and I are confident that Marco is the right person to serve as Genomma's next CEO and continue to accelerate our momentum."

Following Brake's appointment as CEO in 2018, he set in motion a profound strategic and cultural transformation anchored on evolving to a growth mindset while leveraging Genomma's talent to drive growth as a cohesive team. His leadership has been a critical factor to Genomma's achieving significant milestones and to the Company's successful turnaround as a renewed multinational enterprise which today is well positioned to capitalize on important opportunities in its next evolutionary phase. Further, Brake has personally championed Genomma's significant progress related to ESG, including the Company's 2025 Sustainability Vision and Commitments.

Marco Sparvieri is a proven and seasoned business leader with an excellent broad based skill base and a deep understanding of the Company and its brands, who has developed a strong long term relationship with our customers and suppliers. All of which ensures his success in his new role as CEO. He began his tenure at Genomma initiating a transformational period during which he led the development of new Commercial and Supply Chain models, enabling the Company to expand its geographical and multi channel presence while integrating new products within its portfolio.

As Chief Operating Officer, Mr. Sparvieri took an integral role in the subsequent phase of Genomma's 2018 transformation period, and has been key at leading the Company's strategy in the areas of Innovation, Go to Market, Supply Chain and Organization/People development over the last four years. During this period, his role and responsibilities have continued to expand behind a well-designed development plan.

Mr. Sparvieri joined Genomma Lab in 2014 after a successful 20 year career with Procter & Gamble, working in several geographies and roles. He holds a degree in Industrial Engineering from the University of Buenos Aires, Argentina and has participated in several executive programs with top business education institutions.

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Latin America with an expanding international presence. Genomma Lab develops, sells and markets a broad range of Premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. The Company has a sound business model through a unique combination of a new product development process, consumer oriented marketing, a broad retail distribution network and a low‐cost, highly flexible supply chain operating model. For more information visit: www.genommalab.com 
Genomma Lab's shares are listed on the Mexican Stock Exchange under the ticker "LABB" (Bloomberg: LABB:MM).

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe," "anticipate," "expect," "envisages," "will likely result," or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays, supply chain disruptions and other impacts to the business, or on the Company's ability to execute business continuity plans as a result of the COVID-19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products attained by competitors; challenges inherent in new product development; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws; changes in behavior and spending patterns of purchasers of products and services; financial instability of international economies and legal systems and sovereign risk. A further list and descriptions of these risks, uncertainties and other factors can be found within the Company's related filings with the Bolsa Mexicana de Valores. Any forward-looking statement made in this release speaks only as of the date of this release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Genomma Lab Internacional, S.A.B. de C.V.